Superiority:
Topbatt Chemical Co., Ltd., Established in 2019, located in Shenzhen, Guangdong Province, is a Manufacturer and Trading company which specialized in fine chemicals like Pharmaceutical Reference Standards and Stable Isotopes. Our Stable Isotopes product line including 2H Labelled APIs, Reagents and Intermediates, 13C Labelled Substance, 15N Labelled Substance and 18O Labelled Substance.
We own a number of Senior pharmaceutical synthetic engineer, analysis engineer and analytical testing instrument. It make us have more than 1700 varieties compouds with high purity in stock in a short time.
We can provide you not only stock items, but also Custom Synthesis Service.
All of our products provided with COA, HPLC/GC, HNMR, qNMR, MS Spectrum.
Contact us at 0086-18923794376 or email us at yehh@topbatt.net, 24/7 stand by for you.
After-sales issues will be settle>98%d in 24 hours.
Details:
Product Name: Abiraterone Isopropyl Ether
Chemical Name: 3-((3S,8R,9S,10R,13S,14S)-3-isopropoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)pyridine
Molecular Formula: C27H37NO
Molecular Weight: 391.6
CAS#: N/A
Purity: >98%
Appearence: Off-White Solid
Price: Negotiable
Available Document: COA, HPLC/GC, HNMR, qNMR, MS Spectrum
Payment Term: Payment in advance by T/T.
Shipment: Package will dispatched in 7-15 days(According to the date of payment) by air.
Trade Term: EXW, FOB, CFR, DDU, DDP, ect.
Abiraterone Isopropyl Ether is an impurity of Abiraterone. Abiraterone acetate is the 3β-acetate form of its active component abiraterone, a potent inhibitor of androgen biosynthesis. Abiraterone, a pregnenolone-derived 3-pyridyl steroidal compound, potently and irreversibly inhibits cytochrome P450 17 alpha-hydroxylase (CYP17), an important enzyme involved in the synthesis of androgen and cortisol, through a covalent binding mechanism with a value of 50% inhibition concentration IC50 of 72 nM, which is 10 to 30 times greater in potency, due to the 3-pyridyl substitution in its chemical structure, than the inhibition by ketoconazole. In order to improve the low solubility of abirateone, abiraterone acetate has been developed and used for the treatment of castration-resistant prostate cancer (CRPC).
Reference
[1].Charles J Ryan and Michael L Cheng. Abiraterone acetate for the treatment of prostate cancer. Expert Opin. Pharmacother. (2013) 14 (1): 91-96
[2].Tadas S. Vasaitis, Robert D. Bruno and Vincent C.O. Njar. CYP17 inhibitors for prostate cancer therapy. Journal of Steroid Biochemistry & Molecular Biology 125 (2011) 23-31
[3].Guru Sonpavde, Gerhardt Attard, Joaquim Bellmunt, Malcolm D. Mason, Bernard Malavaud, Bertrand Tombal and Cora N. Sternberg. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. EUROPEAN UROLOGY 60 (2011) 270-278